Replimune’s Pivotal Year: All Eyes on 2026 FDA Decision

Replimune US76029N1063

For Replimune and its investors, 2026 is shaping up to be a defining period. After a significant regulatory setback in mid-2025, the company’s prospects are now revitalized, centered on a crucial upcoming decision from the U.S. Food and Drug Administration. The potential approval of its lead candidate, RP1 for advanced melanoma, alongside compelling new clinical data, could mark a dramatic turnaround for the biotech firm.